Double Blind Randomized Controlled Trial to Evaluate the Safety of Lactobacillus Rhamnosus GG ATCC 53103 (LGG) Versus Placebo in Elderly Subjects Receiving Live Attenuated Influenza Vaccine.

Trial Profile

Double Blind Randomized Controlled Trial to Evaluate the Safety of Lactobacillus Rhamnosus GG ATCC 53103 (LGG) Versus Placebo in Elderly Subjects Receiving Live Attenuated Influenza Vaccine.

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Oct 2013

At a glance

  • Drugs Influenza virus vaccine live (Primary) ; Lactobacillus rhamnosus (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions
  • Most Recent Events

    • 09 May 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 08 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top